Daily Endocrinology Research Analysis
Analyzed 47 papers and selected 3 impactful papers.
Summary
Top findings span mechanistic diabetes biology, precision genomics, and pediatric endocrine therapeutics. A Nature Communications study uncovers that branched-chain α-keto acids suppress insulin secretion via LDHA reactivation; a Diabetologia analysis refines MODY variant interpretation and identifies INS NMD-escape loss-of-function as a new MODY cause; and a phase 3 RCT shows once-weekly somapacitan outperforms daily GH in children with Noonan syndrome.
Research Themes
- Metabolic signaling and insulin secretion mechanisms
- Genomic variant interpretation in monogenic diabetes (MODY)
- Long-acting growth hormone therapy optimization in pediatric endocrinology
Selected Articles
1. Branched-chain α-keto acids impair glucose-stimulated insulin secretion in pancreatic β-cells under diabetes by reactivating the LDHA-lactate axis.
Using human islets, mouse models, and β-cell genetics, the study shows BCKAs suppress GSIS by directly binding and activating LDHA, diverting glucose from oxidative metabolism to lactate. Lowering BCKAs improved glucose tolerance and insulin secretion in diabetic mice, linking BCAA dysmetabolism to β-cell dysfunction.
Impact: Reveals a previously unrecognized, druggable axis (BCKA–LDHA) that mechanistically links amino acid metabolism to β-cell failure, challenging prevailing paradigms and opening therapeutic avenues.
Clinical Implications: Targets that reduce circulating BCKAs or modulate LDHA activity could restore β-cell function; dietary counseling to avoid excessive BCAA/BCKA exposure in susceptible patients warrants investigation.
Key Findings
- BCKAs inhibited GSIS across human islets, mouse islets, and β-cells, and correlated inversely with insulin secretory capacity in diabetic humans.
- BCKAs directly bound LDHA, promoted its dimerization, and reactivated the LDHA–lactate pathway, diverting glucose away from the TCA cycle.
- β-cell-specific LDHA deletion rescued GSIS and glucose tolerance in BCKA-fed mice; lowering BCKAs improved glucose tolerance and GSIS in diabetic mice.
Methodological Strengths
- Multi-system validation (human islets, mouse islets, in vivo mice, β-cell genetics)
- Biophysical/mechanistic evidence of direct BCKA–LDHA interaction with functional rescue via β-cell–specific LDHA ablation
Limitations
- Predominantly preclinical models; causal relevance in humans requires interventional studies
- Potential sex-specific and species differences not fully delineated; long-term safety of targeting LDHA/BCKA pathways unknown
Future Directions: Test LDHA inhibitors or BCKA-lowering strategies in translational models and early-phase human trials; define dietary BCAA thresholds impacting β-cell function.
Dysmetabolism of branched-chain amino acid (BCAA) causes insulin resistance in type 2 diabetes, yet its effect on insulin-producing β-cells remains unclear. Here, we demonstrate that branched-chain α-ketoacids (BCKAs), derived from BCAAs, inhibited glucose-stimulated insulin secretion (GSIS) and glucose fluxes across human islets, mouse islets, and mouse β-cells. In diabetic humans, elevated circulating BCKAs negatively correlated with insulin secretory ability. Treatment with BCKA or its impaired catabolism suppressed GSIS in human islets and male mice, while reducing BCKA improved glucose tolerance and GSIS in male and female diabetic mice. Mechanistically, BCKA redirected glucose metabolism from the TCA cycle to the "β-cell disallowed" lactate dehydrogenase A (LDHA)-lactate axis. BCKA directly bound to LDHA, promoting its dimerization and enhancing enzymatic activity. β-cell-specific LDHA ablation restored GSIS and glucose tolerance in BCKA-fed male mice. Our findings demonstrate that BCKA disrupts insulin secretion through LDHA reactivation, linking aberrant BCAA metabolism to β-cell dysfunction in diabetes.
2. Systematic analysis of loss-of-function variants across MODY genes demonstrates gene-specific effects and expands the spectrum of INS variants causing MODY.
Ultra-rare LOF variants show gene-specific enrichment patterns across MODY genes, shaped by NMD status. Critically, heterozygous NMD-escape LOF variants in INS are established as a new cause of MODY, supporting NMD-aware, gene-contextual variant interpretation.
Impact: Refines diagnostic genetics by proving INS NMD-escape LOF as pathogenic and delivering systematic, NMD-aware guidance across MODY genes.
Clinical Implications: Genetic testing pipelines should flag NMD-escape LOF in INS and apply gene-specific, NMD-informed criteria, improving MODY diagnosis and tailored therapy.
Key Findings
- LOF variants were enriched in MODY genes except ABCC8 and KCNJ11, with gene-specific patterns influenced by NMD status.
- Both NMD-triggering and NMD-escape LOF variants were enriched in GCK, HNF1A, and HNF4A, consistent with haploinsufficiency.
- Heterozygous NMD-escape LOF variants in INS represent a newly validated cause of MODY, supported by replication and co-segregation.
Methodological Strengths
- Large case-control framework (5171 suspected MODY cases; 155,501 UK Biobank controls)
- NMD-aware stratification with replication, co-segregation, and in silico protein modeling
Limitations
- Predominantly European ancestry limits generalizability to diverse populations
- Case ascertainment and referral bias possible in suspected MODY cohort; phenotypic detail limited in abstract
Future Directions: Extend analyses to diverse ancestries; develop standardized, NMD-aware ACMG/AMP criteria for MODY genes; evaluate clinical utility in prospective diagnostic workflows.
AIMS/HYPOTHESIS: Accurate interpretation of loss-of-function (LOF) variants in MODY genes is essential for diagnosis but remains challenging, particularly for variants that are predicted to escape nonsense-mediated decay (NMD). We aimed to systematically evaluate the pathogenicity of LOF variants, stratified by NMD-triggering and NMD-escape status, across all known MODY genes. METHODS: We analysed ultra-rare LOF variants (minor allele frequency <1 in 10,000) in 5171 individuals of European ancestry with suspected MODY, compared with 155,501 population-based control individuals from UK Biobank. LOF variants in ABCC8, GCK, HNF1A, HNF4A, HNF1B, INS, KCNJ11, NEUROD1, PDX1 and RFX6 were classified as NMD-triggering or NMD-escape. We tested for gene-level enrichment in cases vs controls. For novel associations, we performed replication in additional MODY patients, assessed familial co-segregation, and undertook in silico protein modelling. RESULTS: LOF variants were significantly enriched in all MODY genes except ABCC8 and KCNJ11. Both NMD-triggering and NMD-escape variants were enriched in GCK, HNF1A and HNF4A, consistent with haploinsufficiency (all p<10 CONCLUSIONS/INTERPRETATION: The pathogenicity of LOF variants in MODY genes depends on gene context and NMD status. Heterozygous NMD-escape LOF variants in INS are a novel cause of MODY. These findings provide systematic gene-level evidence to inform variant interpretation guidelines and improve the accuracy of MODY diagnosis in clinical practice.
3. Once-weekly Somapacitan in Children with Noonan Syndrome: Randomised Controlled Phase 3 Trial.
In a 52-week, randomized, open-label phase 3 sub-trial, once-weekly somapacitan achieved higher annualized height velocity than daily GH in GH-naïve children with Noonan syndrome (10.4 vs 9.2 cm/year; p<0.01) with similar safety and tolerability.
Impact: Demonstrates superiority of a once-weekly GH over daily GH in Noonan syndrome, potentially reducing treatment burden while improving growth outcomes.
Clinical Implications: Supports adopting once-weekly somapacitan as a preferred regimen for eligible Noonan syndrome children, pending longer-term data on adult height and safety.
Key Findings
- Annualized height velocity at 52 weeks was higher with somapacitan vs daily GH (10.4 vs 9.2 cm/year; ETD 1.2, 95% CI 0.32–2.03; p<0.01).
- Height SDS improved more with somapacitan (ΔSDS 1.07 vs 0.75; ETD 0.32, 95% CI 0.16–0.48).
- Safety and tolerability profiles were similar between somapacitan and daily GH over 52 weeks.
Methodological Strengths
- Randomized, multicenter phase 3 design with pre-specified primary endpoint
- Objective growth endpoints with trial registration (NCT05330325)
Limitations
- Open-label design may introduce performance bias despite objective endpoints
- Sample size modest and limited to 52 weeks; long-term outcomes (adult height) pending
Future Directions: Assess long-term adult height, metabolic safety, adherence, and real-world effectiveness; evaluate QoL and caregiver burden reductions.
OBJECTIVE: Daily growth hormone (GH) injections are indicated for the treatment of short stature in children with Noonan syndrome, which presents a treatment burden for the child and their parents/caregivers. Somapacitan is a long-acting, reversible albumin-binding GH, developed for once-weekly administration. The objective of this study is to evaluate efficacy, safety and tolerability of somapacitan versus daily GH in children living with Noonan syndrome. DESIGN: REAL8 (NCT05330325) is a multi-national, multi-centre, randomised, open-labelled, active comparator, phase 3 basket study including four non-GH deficiency indications comprising a 52-week main phase and 104-week extension. Here, we present 52-week results from the REAL8Noonan syndrome sub-study. METHODS: Seventy-seven GH-treatment-naïve, prepubertal boys (aged 2.5 to 11 years) and girls (aged 2.5 to 10 years) with Noonan syndrome were randomized 2:1 to somapacitan 0.24 mg/kg/week or daily GH 0.050 mg/kg/day, administered subcutaneously. RESULTS: The primary endpoint, estimated mean annualized height velocity at week 52, was 10.4 cm/year for somapacitan versus 9.2 cm/year for daily GH (estimated treatment difference [ETD]: 1.2, 95% CI [0.32; 2.03]), confirming non-inferiority and demonstrating superiority of somapacitan compared to daily GH (p<0.01). The estimated change from baseline to week 52 in height standard deviation score was 1.07 and 0.75 for somapacitan and daily GH, respectively (ETD: 0.32, 95% CI [0.16; 0.48]). Somapacitan was well tolerated and had a similar safety profile to daily GH. CONCLUSION: Once-weekly somapacitan was confirmed as non-inferior and demonstrated superiority to daily GH in HV after 52 weeks of treatment in treatment-naïve children living with Noonan syndrome. Similar safety profiles and tolerability were observed for both groups.